Correlation Between Apellis Pharmaceuticals and Vir Biotechnology

Can any of the company-specific risk be diversified away by investing in both Apellis Pharmaceuticals and Vir Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Apellis Pharmaceuticals and Vir Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Apellis Pharmaceuticals and Vir Biotechnology, you can compare the effects of market volatilities on Apellis Pharmaceuticals and Vir Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Apellis Pharmaceuticals with a short position of Vir Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Apellis Pharmaceuticals and Vir Biotechnology.

Diversification Opportunities for Apellis Pharmaceuticals and Vir Biotechnology

0.02

Correlation Coefficient

Apellis Pharmaceuticals  Vir Biotechnology

Significant diversification

The 3 months correlation between Apellis and Vir is 0.02. Overlapping area represents the amount of risk that can be diversified away by holding Apellis Pharmaceuticals and Vir Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vir Biotechnology and Apellis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Apellis Pharmaceuticals are associated (or correlated) with Vir Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vir Biotechnology has no effect on the direction of Apellis Pharmaceuticals i.e., Apellis Pharmaceuticals and Vir Biotechnology go up and down completely randomly.

Pair Corralation between Apellis Pharmaceuticals and Vir Biotechnology

Given the investment horizon of 90 days Apellis Pharmaceuticals is expected to generate 1.12 times more return on investment than Vir Biotechnology. However, Apellis Pharmaceuticals is 1.12 times more volatile than Vir Biotechnology. It trades about 0.01 of its potential returns per unit of risk. Vir Biotechnology is currently generating about -0.04 per unit of risk. If you would invest  4,756  in Apellis Pharmaceuticals on September 26, 2024 and sell it today you would lose (1,424) from holding Apellis Pharmaceuticals or give up 29.94% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Apellis Pharmaceuticals  vs.  Vir Biotechnology

Apellis Pharmaceuticals

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Apellis Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady essential indicators, Apellis Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Vir Biotechnology

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Vir Biotechnology are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively unsteady forward indicators, Vir Biotechnology may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Apellis Pharmaceuticals and Vir Biotechnology

The main advantage of trading using opposite Apellis Pharmaceuticals and Vir Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Apellis Pharmaceuticals position performs unexpectedly, Vir Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will offset losses from the drop in Vir Biotechnology's long position.

The idea behind Apellis Pharmaceuticals and Vir Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.